[1]
|
NIH Consensus Development Panel on Osteoporosis Prevention, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA, 285, 785-795. https://doi.org/10.1001/jama.285.6.785
|
[2]
|
Vestergaard, P., Rejnmark, L. and Mosekilde, L. (2007) Increased Mortality in Patients with a Hip Fracture-Effect of Pre-Morbid Conditions and Post-Fracture Complications. Osteoporosis International, 18, 1583-1593.
https://doi.org/10.1007/s00198-007-0403-3
|
[3]
|
Black, D.M. and Rosen, C.J. (2016) Clinical Practice. Postmenopausal Osteoporosis. The New England Journal of Medicine, 374, 254-262. https://doi.org/10.1056/NEJMcp1513724
|
[4]
|
Akerstrom, G., Hellman, P., Hessman, O., et al. (2005) Parathyroid Glands in Calcium Regulation and Human Disease. Annals of the New York Academy of Sciences, 1040, 53-58. https://doi.org/10.1196/annals.1327.005
|
[5]
|
Wysolmerski, J.J. (2012) Parathyroid Hormone-Related Protein: An Update. The Journal of Clinical Endocrinology & Metabolism, 97, 2947-2956. https://doi.org/10.1210/jc.2012-2142
|
[6]
|
Cusano, N.E., Costa, A.G., Silva, B.C., et al. (2011) Therapy of Osteoporosis in Men with Teriparatide. Journal of Osteoporosis, 2011, Article ID: 463675. https://doi.org/10.4061/2011/463675
|
[7]
|
Makino, A., Takagi, H., Takahashi, Y., et al. (2018) Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide. Calcified Tissue International, 103, 289-297.
https://doi.org/10.1007/s00223-018-0422-4
|
[8]
|
Neer, R.M., Arnaud, C.D., Zanchetta, J.R., et al. (2001) Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. The New England Journal of Medicine, 344, 1434-1441.
https://doi.org/10.3171/foc.2001.11.2.8
|
[9]
|
Saag, K.G., Shane, E., Boonen, S., et al. (2007) Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. The New England Journal of Medicine, 357, 2028-2039. https://doi.org/10.1056/NEJMoa071408
|
[10]
|
Kaufman, J.M., Orwoll, E., Goemaere, S., et al. (2005) Teriparatide Effects on Vertebral Fractures and Bone Mineral Density in Men with Osteoporosis: Treatment and Discontinuation of Therapy. Osteoporosis International, 16, 510-516.
https://doi.org/10.1007/s00198-004-1713-3
|
[11]
|
Bashutski, J.D., Eber, R.M., Kinney, J.S., et al. (2010) Teriparatide and Osseous Regeneration in the Oral Cavity. The New England Journal of Medicine, 363, 2396-2405. https://doi.org/10.1056/NEJMoa1005361
|
[12]
|
Kendler, D.L., Marin, F., Zerbini, C.A.F., et al. (2018) Effects of Teriparatide and Risedronate on New Fractures in Post-Menopausal Women with Severe Osteoporosis (VERO): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial. The Lancet, 391, 230-240. https://doi.org/10.1016/S0140-6736(17)32137-2
|
[13]
|
Cheung, A. and Seeman, E. (2010) Teriparatide Therapy for Alendronate-Associated Osteonecrosis of the Jaw. The New England Journal of Medicine, 363, 2473-2474. https://doi.org/10.1056/NEJMc1002684
|
[14]
|
Hattersley, G., Dean, T., Corbin, B.A., et al. (2016) Binding Selectivity of Abaloparatide for PTH Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology, 157, 141-149.
https://doi.org/10.1210/en.2015-1726
|
[15]
|
Doyle, N., Varela, A., Haile, S., et al. (2018) Abaloparatide, a Novel PTH Receptor Agonist, Increased Bone Mass and Strength in Ovariectomized Cynomolgus Monkeys by Increasing Bone Formation without Increasing Bone Resorption. Osteoporosis International, 29, 685-697. https://doi.org/10.1007/s00198-017-4323-6
|
[16]
|
Chandler, H., Lanske, B., Varela, A., et al. (2018) Abaloparatide, a Novel Osteoanabolic PTHrP Analog, Increases Cortical and Trabecular Bone Mass and Architecture in Orchiectomized Rats by Increasing Bone Formation without Increasing Bone Resorption. Bone, 120, 148-155. https://doi.org/10.1016/j.bone.2018.10.012
|
[17]
|
Bilezikian, J.P., Hattersley, G., Fitzpatrick, L.A., et al. (2018) Abaloparatide-SC Improves Trabecular Microarchitecture as Assessed by Trabecular Bone Score (TBS): A 24-Week Randomized Clinical Trial. Osteoporosis International, 29, 323-328. https://doi.org/10.1007/s00198-017-4304-9
|
[18]
|
Chew, C.K. and Clarke, B.L. (2017) Abaloparatide: Recombinant Human PTHrP (1-34) Anabolic Therapy for Osteoporosis. Maturitas, 97, 53-60. https://doi.org/10.1016/j.maturitas.2016.12.003
|
[19]
|
Miller, P.D., Hattersley, G., Riis, B.J., et al. (2016) Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Randomized Clinical Trial. JAMA, 316, 722-733.
https://doi.org/10.1001/jama.2016.11136
|
[20]
|
Leder, B.Z., O’Dea, L.S., Zanchetta, J.R., et al. (2015) Effects of Abaloparatide, a Human Parathyroid Hormone-Re- lated Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 100, 697-706. https://doi.org/10.1210/jc.2014-3718
|
[21]
|
Reginster, J.Y., Hattersley, G., Williams, G.C., et al. (2018) Abaloparatide Is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. Calcified Tissue International, 103, 540-545. https://doi.org/10.1007/s00223-018-0450-0
|
[22]
|
McClung, M.R., Harvey, N.C., Fitzpatrick, L.A., et al. (2018) Effects of Abaloparatide on Bone Mineral Density and Risk of Fracture in Postmenopausal Women Aged 80 Years or Older with Osteoporosis. Menopause, 25, 767-771.
https://doi.org/10.1097/GME.0000000000001080
|
[23]
|
Leder, B.Z., Tsai, J.N., Jiang, L.A., et al. (2017) Importance of Prompt Antiresorptive Therapy in Postmenopausal Women Discontinuing Teriparatide or Denosumab: The Denosumab and Teriparatide Follow-Up Study (DATA-Follow- Up). Bone, 98, 54-58. https://doi.org/10.1016/j.bone.2017.03.006
|
[24]
|
Bone, H.G., Cosman, F., Miller, P.D., et al. (2018) ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 103, 2949-2957. https://doi.org/10.1210/jc.2018-00163
|
[25]
|
Medscape, FDA Clears Abaloparatide for High-Risk Osteoporosis Patients, 2017, April 28.
https://www.medscape.com/viewarticle/879284
|
[26]
|
Le, Q.A., Hay, J.W., Becker, R., et al. (2018) Cost-Effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate versus Teriparatide Followed by Alendronate in Postmenopausal Women with Osteoporosis in the United States. Annals of Pharmacotherapy, 53, 134-143.
|
[27]
|
Cipriani, C., Irani, D. and Bilezikian, J.P. (2012) Safety of Osteoanabolic Therapy: A Decade of Experience. Journal of Bone and Mineral Research, 27, 2419-2428. https://doi.org/10.1002/jbmr.1800
|
[28]
|
Suen, P.K. and Qin, L. (2016) Sclerostin, an Emerging Therapeutic Target for Treating Osteoporosis and Osteoporotic Fracture: A General Review. Journal of Orthopaedic Translation, 4, 1-13. https://doi.org/10.1016/j.jot.2015.08.004
|
[29]
|
Graeff, C., Campbell, G.M., Pena, J., et al. (2015) Administration of Romosozumab Improves Vertebral Trabecular and Cortical Bone as Assessed with Quantitative Computed Tomography and Finite Element Analysis. Bone, 81, 364-369.
https://doi.org/10.1016/j.bone.2015.07.036
|
[30]
|
Cosman, F., Crittenden, D.B., Adachi, J.D., et al. (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England Journal of Medicine, 375, 1532-1543. https://doi.org/10.1056/NEJMoa1607948
|
[31]
|
Cosman, F., Crittenden, D.B., Ferrari, S., et al. (2018) FRAME Study: The Foundation Effect of Building Bone with 1 Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab. Journal of Bone and Mineral Research, 33, 1219-1226. https://doi.org/10.1002/jbmr.3427
|
[32]
|
Saag, K.G., Petersen, J., Brandi, M.L., et al. (2017) Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. The New England Journal of Medicine, 377, 1417-1427. https://doi.org/10.1056/NEJMoa1708322
|
[33]
|
McClung, M.R., Brown, J.P., Diez-Perez, A., et al. (2018) Effects of 24 Months of Treatment with Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. Journal of Bone and Mineral Research, 33, 1397-1406.
https://doi.org/10.1002/jbmr.3452
|
[34]
|
Lewiecki, E.M., Blicharski, T., Goemaere, S., et al. (2018) A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 103, 3183-3193. https://doi.org/10.1210/jc.2017-02163
|
[35]
|
Claes, K.J., Viaene, L., Heye, S., et al. (2013) Sclerostin: Another Vascular Calcification Inhibitor? The Journal of Clinical Endocrinology & Metabolism, 98, 3221-3228. https://doi.org/10.1210/jc.2013-1521
|
[36]
|
Li, X., Ominsky, M.S., Niu, Q.T., et al. (2008) Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength. Journal of Bone and Mineral Research, 23, 860-869.
https://doi.org/10.1359/jbmr.080216
|
[37]
|
Kang, J.H., Keller, J.J. and Lin, H.C. (2013) Bisphosphonates Reduced the Risk of Acute Myocardial Infarction: A 2-Year Follow-Up Study. Osteoporosis International, 24, 271-277. https://doi.org/10.1007/s00198-012-2213-5
|
[38]
|
盛志峰, 陈瑜, 廖二元. 骨质疏松治疗促骨形成与抗骨吸收药物序贯或联合应用[J]. 中华骨质疏松和骨矿盐疾病杂志, 2015, 8(3): 267-271.
|